Hudson Bay Capital Management
MCRB icon

Hudson Bay Capital Management’s Seres Therapeutics MCRB Stock Holding History

Hudson Bay Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-125,000
Closed -$2.4M – 1400
2025
Q3 		$2.4M Buy
+125,000
New +$1.99M 0.01% 725

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Hudson Bay Capital Management's MCRB Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 50,249 shares — an estimated $727K sold.

Hudson Bay Capital Management first reported a position in MCRB in Q3 2021 and held it in 12 quarters. The position peaked at $6.05M in Q4 2023. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 50,249 Seres Therapeutics shares in Q3 2024, an estimated $727K.
  • Hudson Bay Capital Management first reported a position in Seres Therapeutics in Q3 2021 and held it in 12 quarters.
  • Hudson Bay Capital Management's Seres Therapeutics position peaked at $6.05M in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.